Navigation Links
Postdiagnosis aspirin use reduces risk of dying from colorectal cancer

Regular use of aspirin after colorectal cancer diagnosis may reduce the risk of cancer death, report investigators from Massachusetts General Hospital (MGH), Dana-Farber Cancer Institute and Brigham and Women's Hospital. In the August 12 issue of the Journal of the American Medical Association, the study's authors also find that the aspirin-associated survival advantage was seen primarily in patients with tumors expressing the COX-2 enzyme, a characteristic of two-thirds of colorectal cancers.

"While previous studies by our group and others showed that aspirin and other non-steroidal anti-inflammatory drugs reduce the risk of developing colorectal cancer, this study is the among the first to show that aspirin can also improve survival in patients who have already been diagnosed with colorectal cancers. Moreover, the benefit appeared to be especially strong among patients with cancers that express COX-2," says Andrew Chan, MD, MPH, of the MGH Gastrointestinal Unit, the study's lead author. "This is an important first step toward developing targeted approaches to improving patient outcomes."

Many previous studies have shown that regular use of aspirin and other non-steroidal anti-inflammatory drugs reduces the risk of developing colorectal cancer. In 2007, the same MGH/DFCI research team found that the benefit only applied to tumors overexpressing COX-2, an enzyme believed to drive tumor growth and known to be inhibited by aspirin and related drugs. To test their hypotheses that aspirin would also improve the survival of patients diagnosed with colorectal cancer, again through its inhibition of COX-2, the researchers compiled data from two ongoing prospective research studies the Nurses Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS). Both studies gather comprehensive health information on their participants every two years; data are then analyzed for associations between factors such as medication use and the incidence of several diseases.

The current study focused on 1,279 study participants who were diagnosed with stage 1, 2 or 3 colorectal cancer during their participation in the studies for whom data was available on aspirin use before and after diagnosis. Tumor samples available from 459 participants were analyzed for the expression of COX-2. Study results indicated that patients who regularly took aspirin after their diagnosis had a nearly 30 percent lower risk of dying of colorectal cancer during an average of 11 years after diagnosis than did non-aspirin users. The benefit was especially strong among patients who began using aspirin after diagnosis. In contrast, patients who were aspirin users before diagnosis did not appear to benefit as much from continuing aspirin use after diagnosis. As expected, the survival benefit appeared restricted to patients with COX-2-positive tumors.

"We believe our results could lead to improvements in the therapy of patient with colon cancer," says Charles Fuchs, MD, MPH, of Dana-Farber, the study's senior author. "We're now following up this observational study with a randomized trial to evaluate adding the COX-2 inhibitor celecoxib which is less likely to have the gastrointestinal side effects of aspirin to standard chemotherapy."


Contact: Sue McGreevey
Massachusetts General Hospital

Related medicine news :

1. Aspirin May Stem Deaths From Colorectal Cancer
2. Corgenix to Exhibit AspirinWorks(R) Test at 2009 ISTH Meeting
3. Drug Limits Stomach Trouble in Patients Taking Low-Dose Aspirin
4. Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others
5. Value of Taking Aspirin to Cut Heart Risk Varies
6. Chewable Aspirin More Readily Absorbed
7. Study compares formulations of 3 aspirin types
8. Study compares formulations of three aspirin types
9. Aspirin Lowers Stroke Risk in Peripheral Artery Disease
10. Aspirin Linked to Brain Microbleeds
11. Plavix Plus Aspirin Lowers Stroke Risk
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: